LFT Report Analysis - Intern Summary

ABNORMAL VALUES AT A GLANCE

PATTERN INTERPRETATION

• ALT > AST (ratio 0.57, well under 1): This points away from alcoholic hepatitis (which gives AST:ALT > 2:1) and toward viral hepatitis, NAFLD/NASH, or drug-induced liver injury (DILI).
• ALT is 9x the upper limit of normal (ULN) - this is a significant elevation.
• R-ratio calculation: ALT/ULN ÷ ALP/ULN = (452/49) ÷ (156/120) = 9.2 ÷ 1.3 = ~7.1 → R > 5 confirms hepatocellular injury (not cholestatic).
• Bilirubin is completely normal - a relatively reassuring sign that synthetic function is preserved for now.

DIFFERENTIAL DIAGNOSIS (Priority Order)

1. Acute Viral Hepatitis (most important to rule out first)
   • Hepatitis A (HAV), Hepatitis B (HBV), Hepatitis E (HEV) - all can give this pattern
   • Hepatitis C less likely to present acutely this way but possible
   • EBV, CMV in younger patients
2. NAFLD/NASH (most common in asymptomatic patients)
   • As noted on the lab report itself, and confirmed by Harrison's
   • Look for metabolic risk factors: obesity, T2DM, dyslipidemia, hypertension
3. Drug-Induced Liver Injury (DILI)
   • Any new medication, herbal supplement, traditional remedy, or over-the-counter drug in the past 3 months
4. Autoimmune Hepatitis (AIH)
   • Especially in young women
5. Alcoholic Liver Disease (less likely given AST:ALT < 1)
   • But always ask - AST rarely exceeds 300 in alcoholic hepatitis
6. Wilson's Disease (in patients < 40 years old)

IMMEDIATE WORKUP (Investigations to Order)

• Anti-HAV IgM (Hep A)
• HBsAg, Anti-HBc IgM (Hep B)
• Anti-HCV, HCV RNA (Hep C)
• Anti-HEV IgM (Hep E - especially relevant in South/Southeast Asia)
• EBV/CMV serology if clinically suspected

• Fasting glucose, HbA1c
• Lipid profile (total cholesterol, LDG, HDL, TG)
• CBC with differential
• INR / PT (to assess synthetic function - if abnormal, patient is more sick)
• Serum bilirubin repeat if needed

• Ultrasound abdomen (USG) - look for fatty infiltration, liver size/echotexture, biliary dilatation, portal hypertension signs, splenomegaly

• ANA, ASMA, Anti-LKM1 (autoimmune hepatitis screen)
• Serum ceruloplasmin + 24-hr urine copper (Wilson's if < 40 yrs)
• Alpha-1 antitrypsin level
• Ferritin, transferrin saturation (hemochromatosis)
• FibroScan / FIB-4 index to assess fibrosis stage

TREATMENT AND MANAGEMENT

• Strict rest, adequate hydration, high-calorie soft diet
• Stop all potentially hepatotoxic drugs - review all medications and supplements
• Avoid alcohol completely
• Avoid paracetamol/acetaminophen unless dose is minimal and clearly necessary
• Monitor LFTs weekly initially

• Hepatitis A / E: Supportive care only. Most self-limiting. Monitor for fulminant hepatic failure signs (encephalopathy, coagulopathy, rising bilirubin)
• Hepatitis B (acute): Supportive in most cases. Antiviral therapy (tenofovir or entecavir) indicated if: INR > 1.5, severe jaundice, or protracted course
• Hepatitis C: Refer for direct-acting antivirals (DAAs) - treatment is now highly effective

• Weight loss is the cornerstone (even 5-10% body weight loss significantly reduces ALT)
• Exercise (150 min/week of moderate aerobic activity)
• Control diabetes, hypertension, dyslipidemia
• No specific drug approved universally; resmetirom (Rezdiffra) was approved in 2024 for MASH with fibrosis
• Follow-up LFTs in 3-6 months

• Identify and withdraw the offending drug - this is the most important step
• N-acetylcysteine (NAC) only if acetaminophen toxicity
• Monitor for resolution

• Prednisolone ± azathioprine - refer to hepatology

RED FLAGS - Admit/Escalate If:**

• Rising bilirubin (jaundice worsening)
• INR / PT prolonged - indicates failing synthetic function
• Signs of hepatic encephalopathy (altered consciousness, asterixis)
• AST/ALT rising rapidly (> 1000 IU/L) - suggests acute severe hepatocellular necrosis
• Hypoglycemia

SUMMARY FOR YOUR NOTES

Pattern: Hepatocellular injury (ALT-dominant, bilirubin spared, AST:ALT < 1) Most likely: Viral hepatitis vs. NAFLD vs. DILI Priority action: Viral hepatitis serology + INR + USG abdomen Key safety net: If bilirubin rises or INR becomes abnormal, escalate urgently

• Harrison's Principles of Internal Medicine 22e, Chapter 348 - Evaluation of Liver Function
• Washington Manual of Medical Therapeutics - Biochemical Abnormalities (DILI section)
• Kwo et al., Gastroenterology 2026 - Evaluation of Abnormal Liver Biochemical Test Results

Serum Bile Acids Report Analysis - Intern Summary

TEST RESULT AT A GLANCE

IS THIS ACTUALLY NORMAL?

• If the patient is pregnant with pruritus (itching without rash, especially palms/soles, worse at night): A bile acid > 10 µmol/L in the presence of pruritus is diagnostic of Intrahepatic Cholestasis of Pregnancy (ICP/OC), regardless of whether it falls below the lab's reference of 19.
• If asymptomatic and non-pregnant: This is a truly normal result - no further action needed.
• If on UDCA therapy: The assay itself may be measuring UDCA (the drug), artificially elevating the result. LCMS/MS method should be used for accurate measurement, as noted on the report.

Per Goldman-Cecil Medicine: "The diagnosis of intrahepatic cholestasis of pregnancy is based upon symptoms and a total bile acid level greater than 10 µmol/L in the absence of another explanation."

LIKELY CLINICAL SCENARIO: ICP (Intrahepatic Cholestasis of Pregnancy)

1. Pruritus - generalized, worse at night, no primary rash (only excoriations)
2. Bile acids > 10 µmol/L (this patient has 17.70 - above the diagnostic threshold)
3. Second or third trimester of pregnancy
4. No other explanation (no rash disease, no primary skin pathology)

DIAGNOSIS: Intrahepatic Cholestasis of Pregnancy (ICP)

FETAL RISK PROFILE

INVESTIGATIONS TO ORDER

• LFTs: AST, ALT (often elevated in ICP - as seen in this patient's previous report!)
• Bilirubin (direct + total)
• Repeat bile acids in 1-2 weeks (as the lab itself recommends)
• PT/INR (fat malabsorption in cholestasis can cause vitamin K deficiency)
• GGT
• Hepatitis B, C serology (to rule out viral cause)
• Ultrasound abdomen (rule out gallstones, biliary disease)

• Non-stress test (CTG) - regular fetal wellbeing assessment
• Biophysical profile
• Serial growth scans
• Amniotic fluid index

Note: Bile acids on this report (17.70) combined with the elevated ALT/AST from the previous LFT report (ALT 452, AST 257) together make ICP the most likely unifying diagnosis.

TREATMENT & MANAGEMENT

First-Line Drug Treatment

• Dose: 300 mg twice daily (can titrate up to 10-15 mg/kg/day)
• Reduces pruritus symptoms
• Improves liver enzyme levels and bile acid levels
• Important caveat: Recent large RCTs (PITCHES trial) showed UDCA does NOT significantly improve fetal outcomes, but it remains first-line for maternal symptom relief
• Note from report: If patient is already on UDCA, request LCMS/MS testing for accurate bile acid measurement

Symptom Relief for Pruritus

• Chlorphenamine (antihistamine) at night for sleep disturbance
• Cool baths, loose clothing, emollients (calamine lotion)
• Avoid hot environments

Monitoring Schedule

• Bile acids every 1-2 weeks (as stated on the report)
• LFTs every 1-2 weeks
• If bile acids rise toward 40 or 100 µmol/L, escalate management

Delivery Timing (current evidence - based on bile acid level)

Per Goldman-Cecil: "Women with bile acid levels below 100 µmol/L are offered delivery at 36-39 weeks gestation."

POSTPARTUM MANAGEMENT

• Symptoms typically resolve within days of delivery
• Repeat LFTs at 6-8 weeks postpartum to confirm resolution
• Non-hormonal contraception until LFTs normalize
• Estrogen-containing OCP: caution - may precipitate recurrence
• Warn patient: Recurrence risk in future pregnancies is 60-70%
• Screen for: gallstone disease (higher long-term risk), primary biliary cholangitis

IMPORTANT DIFFERENTIAL DIAGNOSES TO EXCLUDE

1. Pre-eclampsia with liver involvement (check BP, proteinuria, uric acid)
2. HELLP syndrome (hemolysis, elevated liver enzymes, low platelets - check CBC)
3. Acute fatty liver of pregnancy (check glucose, coagulation)
4. Viral hepatitis (B, C, E - especially Hep E in endemic areas)
5. Gallstone disease / biliary obstruction (USS abdomen)
6. Skin conditions (atopic eruption, PUPPP - characterized by rash unlike ICP)

SUMMARY FOR YOUR NOTES

Result: Bile acids 17.70 µmol/L - technically within lab reference but above the 10 µmol/L diagnostic threshold for ICP Diagnosis: Intrahepatic Cholestasis of Pregnancy (Mild) - if pregnant with pruritus Priority action: Confirm with LFTs (already done - ALT elevated!), repeat bile acids in 1-2 weeks, start UDCA, initiate fetal monitoring Safety net: Rising bile acids toward 100 µmol/L = escalate to MFM/high-risk OB for early delivery planning

• Goldman-Cecil Medicine, Chapter 221 - Liver Disease in Pregnancy
• Hobson et al. - JOGC Guideline No. 452: Diagnosis and Management of ICP (2024)
• Dajti et al. - ICP, Nature Reviews Disease Primers (2025)

Integrated Diagnosis from Both Reports - Intern Clinical Summary

SUMMARY OF BOTH REPORTS

PRIMARY DIAGNOSIS: Intrahepatic Cholestasis of Pregnancy (ICP)

Why ICP fits BEST:

1. Bile acids > 10 µmol/L (17.70) is the diagnostic threshold for ICP per Goldman-Cecil Medicine
2. Elevated ALT/AST is expected and characteristic of ICP - transaminases are elevated in 60-80% of ICP cases as part of the cholestatic liver injury
3. GGT and ALP elevation are consistent with cholestatic process of ICP
4. Normal bilirubin - typical of ICP (jaundice is uncommon in mild-moderate ICP)
5. AST:ALT < 1 - fits ICP (viral hepatitis also gives this, but bilirubin would usually be elevated in symptomatic viral hepatitis at these ALT levels)
6. The lab itself stated the bile acid test was ordered in context of pruritus and pregnancy

Why Acute Viral Hepatitis is LESS likely (but must still be excluded):

Per Creasy & Resnik's Maternal-Fetal Medicine: "Viral hepatitis is the most common cause of jaundice during pregnancy" - but this patient has NO jaundice (bilirubin is normal), which shifts the balance toward ICP.

Why NAFLD/Fatty Liver is UNLIKELY here:

• NAFLD causes only mild transaminase elevation (usually < 3x ULN)
• This patient has 9x ALT elevation - far too high for simple fatty liver
• NAFLD does not cause bile acid elevation
• NAFLD is a chronic, slowly progressive condition - not an acute presentation
• The lab's own note says "NAFLD is most common in asymptomatic patients" - this patient has symptoms (pruritus)

NAFLD/fatty liver is essentially ruled out as the primary diagnosis at this ALT level.

CLINICAL DECISION TREE

Pregnant patient + Pruritus + LFT abnormal + Bile acids > 10
         |
         ↓
   PRIMARY: ICP (Mild - Bile acids < 40 µmol/L)
         |
         ↓
   MUST RULE OUT urgently:
   ├── Hepatitis E (most dangerous in pregnancy - can cause fulminant liver failure)
   ├── Hepatitis B (acute)
   ├── Hepatitis A
   ├── Hepatitis C
   ├── HELLP Syndrome (elevated LFTs + thrombocytopenia + hemolysis)
   └── Acute Fatty Liver of Pregnancy (AFLP)

Per Park's Preventive Medicine: "Fulminant hepatitis occurs more frequently during pregnancy [with Hep E]. Pregnant women are at greater risk."

CONFIRMATORY INVESTIGATIONS TO ORDER NOW

TIER 1 - Urgent (Order Immediately)

TIER 2 - Important (Order within 24-48 hrs)

TIER 3 - Fetal Monitoring (Start now)

DANGER SIGNS - Escalate Immediately If:

YOUR WORKING DIAGNOSIS STATEMENT

"Pregnant patient in 2nd/3rd trimester presenting with pruritus. LFT shows hepatocellular injury pattern (ALT 9x ULN, AST:ALT < 1, normal bilirubin). Serum bile acids elevated at 17.70 µmol/L (above 10 µmol/L diagnostic threshold). Primary diagnosis: Intrahepatic Cholestasis of Pregnancy (ICP), mild. Acute viral hepatitis (especially Hepatitis E) and HELLP syndrome to be excluded urgently with serological and haematological workup."

BOTTOM LINE FOR YOUR MANAGEMENT TODAY

1. Start UDCA 300 mg BD for symptom relief (do not wait for serology results)
2. Send urgent viral serology panel (HAV, HBV, HCV, HEV)
3. Send CBC, PT/INR, blood glucose, LDH, blood smear to exclude HELLP and AFLP
4. Check BP and urine protein to exclude pre-eclampsia
5. USS abdomen - within 48 hours
6. Begin fetal monitoring - CTG/NST now
7. Repeat bile acids and LFTs in 1-2 weeks
8. Document gestational age - delivery timing depends on bile acid trend

• Creasy & Resnik's Maternal-Fetal Medicine - Chapter 64: Liver Disease in Pregnancy
• Goldman-Cecil Medicine - Chapter 221: Intrahepatic Cholestasis of Pregnancy
• Park's Preventive Medicine - Hepatitis E in Pregnancy
• Hobson et al. JOGC Guideline No. 452: Diagnosis & Management of ICP, 2024

Is ICP Curable? Yes - Complete Treatment Guide

THE SHORT ANSWER

Per Goldman-Cecil Medicine: "Following delivery, symptoms typically resolve in several days, and aminotransferase levels gradually decline."

COMPLETE TREATMENT PLAN

STEP 1 - FIRST-LINE DRUG: Ursodeoxycholic Acid (UDCA)

• Reduces pruritus (itching) - usually within 1-2 weeks
• Lowers serum bile acid levels
• Improves ALT/AST and LFTs
• Replaces toxic bile acids with non-toxic UDCA in the bile acid pool

• Does NOT prevent stillbirth (the PITCHES RCT showed this clearly)
• Does NOT cure the underlying transport defect
• Does NOT eliminate the need for delivery planning

STEP 2 - SYMPTOM RELIEF (Pruritus Management)

• Rifampicin 150-300 mg/day - second-line; reduces bile acid absorption; use cautiously (hepatotoxic at higher doses, limited safety data in pregnancy)
• Cholestyramine - bile acid sequestrant; reduces gut absorption; safe in pregnancy but impairs fat-soluble vitamin absorption (give separately)

STEP 3 - VITAMIN K SUPPLEMENTATION

STEP 4 - FETAL MONITORING PLAN

Note: No monitoring method has been proven to predict sudden fetal death in ICP. This is why delivery timing - not just monitoring - is the primary fetal intervention.

STEP 5 - PLANNED DELIVERY (The Definitive Treatment)

Per Goldman-Cecil: "Women with bile acid levels below 100 µmol/L are offered delivery at 36-39 weeks gestation." Per AGA 2024 Clinical Practice Update (Kothari et al.): Diagnosis based on bile acids > 10 µmol/L; treatment should follow current guidelines.

STEP 6 - POSTPARTUM CARE

WHAT HAPPENS IF UNTREATED?

LONG-TERM PROGNOSIS FOR MOTHER

SUMMARY TABLE FOR YOUR NOTES

• Goldman-Cecil Medicine - Chapter 221: Liver Disease in Pregnancy (Treatment & Prognosis)
• AGA Clinical Practice Update on Pregnancy-Related GI and Liver Disease, Gastroenterology 2024
• JOGC Guideline No. 452: Diagnosis and Management of ICP, 2024
• SOMANZ Consensus Statement on ICP, 2023